Sema20

Description

Semaglutide Peptide Overview

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist analog engineered from the native GLP-1 sequence for greatly extended stability and half-life. It is one of the most studied incretin peptides in metabolic research, valued for its potent and selective activity at the GLP-1 receptor.

GLP-1 Receptor Activation

Semaglutide binds and activates the GLP-1 receptor, an incretin receptor central to glucose and appetite regulation. In research models this drives glucose-dependent insulin secretion while suppressing glucagon, effects studied extensively in models of glucose homeostasis.

Appetite and Energy-Balance Research

A major focus of GLP-1 research is central appetite signaling. Semaglutide is studied for its action on hypothalamic pathways that influence satiety, food intake and energy balance in research models.

Slowed Gastric Emptying

Semaglutide is studied for slowing gastric emptying, a mechanism that contributes to post-meal glucose control and prolonged satiety signaling in research settings.

Extended Half-Life Design

Structural modifications, including a fatty-acid chain that promotes albumin binding, give semaglutide a long duration of action compared with native GLP-1 — a key subject of pharmacokinetic research.

Specifications

• CAS Number: 910463-68-2
• Molecular Formula: C187H291N45O59
• Molar Mass: 4113.58 g/mol
• Class: GLP-1 receptor agonist analog (peptide)
• Storage: Refrigerate after reconstitution.
• Form: Lyophilized powder in a sterile glass vial.
• Purity: Minimum 99%
• Quantity: 20mg per vial
• Color: White

Important Note: This product is intended solely for in vitro laboratory research by licensed professionals. It is not approved by the FDA for human or animal use and should not be misbranded, misused, or mislabeled as a drug, food, supplement, or cosmetic.

References:

1. Knudsen L.B., Lau J. – The discovery and development of liraglutide and semaglutide – Frontiers in Endocrinology
2. Marso S.P. et al. – Semaglutide and cardiovascular outcomes (SUSTAIN-6) – New England Journal of Medicine
3. GLP-1 receptor pharmacology of semaglutide – Diabetes
4. Semaglutide and central appetite regulation – Cell Metabolism